Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product Pharmaceutical Investing
UNIVERSAL IBOGAINE ANNOUNCES WORLD-CLASS CLINICAL TRIAL PARTNERS IN ADVANCE OF CLINICAL TRIAL APPLICATION FOR IBOGAINE IN OPIOID USE DISORDER Pharmaceutical Investing
Numinus Announces Cancellation and Rescheduling of Annual General Meeting of Shareholders Pharmaceutical Investing
NeonMind Appoints Canadian Medical Leader in Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC to Its Specialty Clinics Advisory Board Psychedelics Investing
Levitee Labs Signs Retail Distribution Agreement with Body Energy Club for MONKE Nutraceuticals Psychedelics Investing
Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial Psychedelics Investing
Levitee Labs Partners with Canntab Therapeutics to Provide Alternatives to Opioids Psychedelics Investing
